Posts by Michael Lawrence, PhD
-
"DrugMap" Expected to Accelerate Cancer Drug Discovery
Liron Bar-Peled, PhD, Michael Lawrence, PhD, and colleagues have developed "DrugMap," an atlas of cysteine ligandability compiled across 416 cancer cell lines that lays the groundwork for precision anti-cancer drugs to be systematically developed for additional classes of oncogenic drivers.
-
Not All Recurrent Mutations Are Cancer Drivers
Mutation frequency can be misleading—DNA "hairpins" are associated with recurrence of cancer mutations outside of known drivers.
Biography
Michael Lawrence, PhD, is a principal investigator in the Krantz Family Center for Cancer Research at Mass General Cancer Center and an assistant professor of Pathology at Harvard Medical School.
Mass General Brigham Cancer Institute
Mass General Brigham Cancer Institute unites leading experts and resources across our academic medical centers, making it one of the nation’s top providers of cancer care.